News | October 06, 2011

Cambridge Heart Study Finds MTWA Effective in Detecting Ischemia

October 6, 2011 – Cambridge Heart Inc. announced it has concluded data review for the company’s microvolt T-wave alternans-computer-aided detection (MTWA-CAD) feasibility study. The data suggest MTWA is a statistically significant predictor of ischemic events. In addition, the data revealed instances where the company's MTWA test identified underlying coronary artery disease that was not identified by other standard diagnostic modalities.

Commenting on the data, Richard Cohen, M.D., chairman of the company’s Scientific Advisory Board and Whitaker professor in biomedical engineering at the Massachusetts Institute of Technology, stated, “The results of the review are very promising, suggesting that microvolt T-wave alternans is predictive of ischemic events in cardiac patients undergoing routine stress testing.”

The feasibility study provided Cambridge Heart with the information required to design a multi-center, prospective clinical trial intended to provide the basis for regulatory approval. Accordingly, the company has decided to conclude the enrollment in its MTWA-CAD study, and commence design of the prospective clinical trial.

For more information: www.cambridgeheart.com

Related Content

HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function
News | ECG | April 27, 2018
HeartSciences announced the results of a clinical study of its electrocardiography device that applies continuous...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG | December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG | August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG | August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG | July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG | January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG | October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG | November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG | October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG | September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
Overlay Init